Journal of Pharmaceutical Research International



32(22): 1-10, 2020; Article no.JPRI.61002 ISSN: 2456-9119 (Past name: British Journal of Pharmaceutical Research, Past ISSN: 2231-2919, NLM ID: 101631759)

Effects of Ropivacaine Hydrochloride on the Expression of Type I Interferon and Its Receptor in SH-SY5Y Cells

Xianjie Wen^{1,2*#}, Zhaoxia Wu^{2#}, Weidong Lin^{3#}, Yiqun Li^{4*} and Xiaoping Wang^{1*}

¹Department of Pain Management, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, China.

 ²Department of Anesthesiology, The Second People's Hospital of Foshan City, The Second School of Clinical Medicine, Southern Medical University, Foshan, Guangdong Province, China.
³Department of General Surgery, The Second People's Hospital of Foshan City, The Second School of Clinical Medicine, Southern Medical University, Foshan, Guangdong Province, China.
⁴Department of Orthopaedics, The Second People's Hospital of Foshan City, The Second School of Clinical Medicine, Southern Medical University, Foshan, Guangdong Province, China.

Authors' contributions

This work was carried out in collaboration among all authors. Author XW designed and implemented the experiments and wrote the paper. Author YL collected the data and performed the statistical analysis. Authors XW, WL and ZW implemented the experiments. Author WX designed the experiment and performed the statistical analysis. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2020/v32i2230766 <u>Editor(s):</u> (1) Dr. Giuseppe Murdaca, University of Genoa, Italy. <u>Reviewers:</u> (1) Carlos Darcy Alves Bersot, Hospital Federal da Lagoa, Brazil. (2) Anahita Punj, Kaloji Narayana Rao University of Health Sciences, India. Complete Peer review History: <u>http://www.sdiarticle4.com/review-history/61002</u>

Original Research Article

Received 02 July 2020 Accepted 08 September 2020 Published 11 September 2020

ABSTRACT

Nerve injury caused by local anesthetics is a hot issue that people pay close attention to, and its mechanism has not been fully clarified. Type I interferon (I-IFN) is an important factor in regulating inflammatory response. In this study, SH-SY5Y cells were injured by ropivacaine hydrochloride in vitro. The cell viability, apoptosis rate, mRNA and protein expression of I-IFN and its receptor IFNAR, as well as the contents of inflammatory cytokines TNF- α , IL-6 and IL-10 were detected to explore the correlation between I-IFN and neurotoxicity induced by ropivacaine hydrochloride. The results showed that after treated with ropivacaine hydrochloride, the cell viability was decreased, the apoptosis rate was increased, the mRNA and protein expressions of IFN- α , IFN- β , IFNAR1 and

*Corresponding author: E-mail: lyqun0757@163.com, txp2938@jnu.edu.cn, xjwen166@163.com; [#]The co-first author IFNAR2 were up-regulated, and the contents of inflammatory factors TNF - α , IL-6 and IL-10 were increased. These results suggest that type I interference and its receptor are associated with neurotoxicity of local anesthetics.

Keywords: Type I interference; inflammatory reaction; ropivacaine hydrochloride; neurotoxicity.

1. INTRODUCTION

Interferon was identified and isolated as early as 1957, it is a cytokine protein superfamily and plays an important role in inflammatory response and innate immunity of microorganisms [1-4]. Interferon is mainly divided into type I interferon I-IFN (IFN- α and IFN- β) and type II interferon (IFN-y). Recently, type III interferon (IFN- λ) has been found. The normal central nervous system contains a certain amount of type I interferon to maintain the normal immune function of the body. Although type I interferon can resist the infection of virus, bacteria and other microorganisms, the increased expression of type I interferon can aggravate the damage of central nervous system, lead to inflammatory reaction, and is not conducive to the repair of neurons[5,6]. I-IFN also plays an important role in aseptic inflammation. The increased expression of I-IFN can aggravate the injury of aseptic inflammation. I-IFN promotes inflammatory response, induces proinflammatory gene transcription, promotes the secretion of inflammatory factors (TNF - α, IL-6, IL-1 β) through a variety of signal cascades, including the classic JAK1-STAT signaling pathway, which aggravates the inflammatory reaction and causes damage to the body [7-10].

Inflammation is one of the important mechanisms of neurotoxicity injury induced by local anesthetics [11-12]. Studies have shown that tumor necrosis factor alpha (TNF- α) and its receptor are important factors in the regulation of central and peripheral neurotoxic injury. Knockout of TNF- α can reduce the apoptosis of hippocampal CA1 neurons. As well as, the expression of TNF- α and its receptor in spinal cord is increased in chronic neuropathic pain model. TNF- α and its receptor mediated TNF signaling pathway play an important role in neurotoxic injury induced by local anesthetics[13,14]. Inhibition of the expression of TNF- α and TNF-R1 (TNF receptor 1) can significantly improve the neurotoxic injury induced by bupivacaine.

Our previous study found that after the injury of SH-SY5Y cells induced by ropivacaine hydrochloride, cell viability decreased and apoptosis increased, which was closely related to CaMKII and T-type calcium channels [15-16].

The changes of I-IFN and its receptor expression and the inflammatory factors (TNF - α , IL-6, IL-10) after the injury of SH-SY5Y cells induced by ropivacaine hydrochloride are not clear. In this study, we observed the effects of ropivacaine hydrochloride on the expression of of I-IFN and its receptor of the SH-SY5Y cells. As well as, we detected the changes of the inflammatory factors (TNF - α , IL-6, IL-10) of the SH-SY5Y cells treated with ropivacaine hydrochloride.

2. MATERIALS AND METHODS

2.1 Cell Culture and Experiment Protocol

SH-SY5Y cells passaged in our laboratory, were cultured in Dulbecco's Modified Eagle Medium (DMEM medium) with 10% FBS and 1% penicillin streptomycin solution at 37°C and 5% CO_2 . There were two groups in this experiment, the cell in control group was treated with normal medium to culture, the cell in experimental group was treated with 3mM ropivacaine hydrochloride (AstraZeneca AB, Sweden) for 4 hours.

2.2 MTT Assay for Cell Viability

SH-SY5Y cells in control group were cultured at 37°C and 5% CO2. After the cell in experimental group treated with 3 mM ropivacaine hydrochloride for 4 h, 10µl MTT (BIOSHARP Co. Ltd, Hefei, China) was added into each well, and was cultured at 37 °C for 4 h; the medium was removed and 150 µ I DMSO was added to the cell for 10 min; the absorbance of each well was determined by enzyme-linked immunosorbent assay (OD 568). The ratio of the difference between the OD 568 value of the control group and the OD 568 value of the blank control well to the OD 568 value of the control group was regarded as 100%. The difference between the OD 568 value of the experimental group and the OD 568 value of the blank control well and the control group was the cell viability of the experimental group.

2.3 The Apoptosis Rate was Detected by Flow Cytometry

SH-SY5Y cells were cultured overnight at 37 °C with 5% CO2. The cells in experimental group were treated with 3 mM ropivacaine

hydrochloride for 4 h. Then cells were collected, centrifuged at 1200 rpm for 5 min, supernatant was removed and resuspended with PBS; cells were rinsed twice with PBS at 1200 rpm for 5 min; the operation was carried out according to the operation instructions of annexin V-FITC / PI apoptosis detection kit (Nanjing Kaiji biology, China): 500 μ I binding buffer was added to resuspend cells; 5 μ I annexin V-FITC and 5 μ I PI were added and mixed. The apoptosis rate was detected by flow cytometry at room temperature and protected from light for 5-15 min reaction.

2.4 Real-time PCR

Real-time PCR was used to detect the expression of I-IFN (IFN-α, IFN-β, IFNAR1, IFNAR2) mRNA. After treated according to the experimental protocol, the cells were collected and lysed for 10 min with 1 ml Trizol reagent. Add 200µl chloroform, place at room temperature for 5 minutes, centrifugation at 4 °C, 12000rpm for 15min, take the upper water phase (about 400µl), add 400µl isopropanol and mix at room temperature for 10min, centrifuge at 4 °C, 12000rpm for 10min. Discard the supernatant, add 1ml of 75% ethanol without RNase, vortex mixing at 4 °C, 10000rpm, centrifugation for 5min, discard the supernatant, dry RNA in air for 5-10min, and dissolve the precipitate in 20µl DEPC water. RNA concentration was measured by spectrophotometer. The total RNA was stored in -80 °C refrigerator. The reverse transcriptase system consisted of RNA 5µg, oligo (dT) 18 (10µM) 2µ I, dNTP (2.5 mM) 4µI, 5 × Hiscript buffer 4µl, Hiscript reverse transcriptase 1µl, ribonuclease inhibitor 0.5µl, and ddH₂O to 20µl. The reaction conditions were as follows: 25 °C for 5 min, 50°C for 15 min, 85°C for 5 min, 4°C for 10 min. The PCR reaction system was cDNA 4µl, 10µM forward primer 0.4µl, 10µM reverse primer 0.4µl, SYBR Green master mix 10µl, 50×Rox reference dye 0.4µl, ddH₂O 4.8µl. The primers synthesized Wuhan were by Qingke Biotechnology Co., Ltd (Tab1). The reaction conditions were as follows: 50 °C 2 min, 95°C 10 min; 95 °C 30 sec, 60 °C30 sec, 40 cycles. The dissolution curve was drawn and the expression of the target mRNA were regarded as 2 $^{-\Delta CT}$.

2.5 WB Detection of IFN- a, IFN-β, IFNAR1 and IFNAR2

After treatment according to the experimental protocol, the supernatant was removed, and 4°C PBS 1 ml was added to wash cells for three times. Then the cell plate was placed on the ice.

Lysate containing PMSF (0.1 mM) 120µl were added into each well to lyse for 30 min. Then the cell fragments and lysate were transferred to a 1.5 ml centrifuge tube. Centrifugation was performed at 12 000 rpm at 4°C for 5 min. The centrifuged supernatant was transferred into 0.5ml centrifuge tube and stored at - 20°C. Take 2µl protein sample, and determine OD568 with BCA kit by microplate, and calculate the protein concentration of the sample. The protein samples were denatured in boiling water for 10 min, cooled to room temperature, and then stored at - 20°C. 5% concentrates and 12% separation gums were prepared respectively, and 40 µg samples of total protein were collected from each sample. Take out the gel according to the cut strip of Marker. The PVDF membrane was soaked in5% TBST and skimmed milk powder (blocking solution) and sealed for 2 hours at room temperature. The PVDF membrane was immersed in the first antibody [GAPDH,1:1000(Hangzhou Xianzhi biology Co., Ltd,China); IFN-(Abclonal, а Boston, USA),1:500,IFN-β (Abclonal, Boston, USA),1:500;IFNAR1 (Abclonal, Boston, USA),1:500 and IFNAR2 (Abclonal, Boston, USA),1:500] incubation solution and incubated overnight at 4 °C. HRP labeled secondary antibody was added into the solution, diluted with 1:50000, and incubated for 2 h at room temperature. Mix the reinforcement solution and stable peroxidase solution in ECL reagent at the ratio of 1:1, drop the working solution on the PVDF film, react for several minutes, after the fluorescence band is obvious, use filter paper to excess substrate absorb the solution, cover with fresh-keeping film, after X-ray film is pressed, put in developing solution for developing, fixing solution for fixing, and develop film. The gray value of film was analyzed by Bandscan.

2.6 The Contents of TNF - α, IL-6 and IL-10 Were Detected by ELISA

The cells were centrifuged at 3000 rpm for 10 min, and the supernatant was collected for detection. According to the steps of ELISA kit (Elabscience Biotechnology Co.,Ltd, Wuhan, China) for IL-6, IL-10, TNF - α , blank hole, standard hole and sample hole were set respectively. 100 μ I of sample diluent was added to the blank hole, and 100 μ I of standard substance or sample to be tested was added to the remaining hole. They were incubated at 37°C for 90 minutes. Discard the liquid in the pore, add 100 μ I biotinylated antibody working solution into

Name	Primer	Sequence	Size
GAPDH	Forward	5'- TCAAGAAGGTGGTGAAGCAGG -3'	115bp
	Reverse	5'- TCAAAGGTGGAGGAGTGGGT -3'	
IFN-a	Forward	5'-CCTCGCCCTTTGCTTTAC -3'	99bp
	Reverse	5'-ATTCTGTCATTTGTGCCAG -3'	
IFN-β	Forward	5'-TCCTGGCTAATGTCTATC -3'	188bp
	Reverse	5'-TTCCACTCTGACTATGGT -3'	
IFNAR1	Forward	5'-ACTCATTTACACCATTTC -3'	108bp
	Reverse	5'-CACTATCTTTTGTTCCAG -3'	
IFNAR2	Forward	5'-TTTGAGATTGTTGGTTTTAC -3'	150bp
	Reverse	5'-GTTTCCTTTTATTTCGGGTT -3'	

Table 1. The primer of GAPDH, IFN- a, IFN-β, IFNAR1 and IFNAR2

each well, and incubate at 37 °C for 1 hour. Discard the liquid, add 100µl of enzyme conjugate working solution into each well, and incubate at 37 °C for 30 minutes. Discard the liquid in the well, add 90µl TMB to each well, and incubate for 15 minutes in dark at 37 °C. Add 50µl termination solution to terminate the reaction. The optical density (OD value) of each well was measured at 450 nm wavelength by enzyme labeled instrument. The contents of TNF- α , IL-6 and IL-10 were calculated according to the standard and OD values.

3. RESULTS

3.1 Cell Viability

The cell viability of the cells in the normal group was regarded as 100%. After treated with 3mM ropivacaine hydrochloride for 4h, the cell viability was (74.33 ± 3) %. Compared with normal group, the cell viability of the cells in ropivacaine group significantly decreased, Fig 1.

3.2 Apoptosis Rate

2.7 Statistical Analysis

All data were expressed as Mean \pm SD. Paired t test was used to analysis the data between the two groups, P < 0.05 was considered as statistically significant difference.

The apoptosis rate of the cells in Normal group was (4.59 ± 0.15) %. After treated with 3mM ropivacaine hydrochloride for 4h, the apoptosis rate was increased to (20.02 ± 0.55) %, and the difference was statistically significant (*P*<0.05).



Fig. 1. The cell viability of the cells in each group (Mean ±SD, n=3). ^a*P*<0.05 vs the cells in normal group

3.3 The mRNA Expression of IFN-α, IFN-β, IFNAR1, IFNAR2

After treated with ropivacaine hydrochloride for 4h, the mRNA expressions of IFN- α , IFN- β , IFNAR1, IFNAR2 were detected. The mRNA expression of the cells in Normal group were regarded as 1, the mRNA expression of IFN- α , IFN- β , IFNAR1, IFNAR2 of the cells in Ropivacaine group were 2.60 ± 0.15, 2.3 ± 0.20, 1.74 ± 0.07, 2.04 ± 0.15, respectively. Compared with the cell in Normal group, there were significant down-regulation of the mRNA expression in Ropivacaine group, Fig. 3.

3.4 Expression of IFN-α, IFN-β, IFNAR1 and IFNAR2 Detected by Western Blotting

The expression of IFN- α ,IFN- β ,IFNAR1 and IFNAR2 of the cells in normal group were 0.30 ± 0.02, 0.43 ± 0.14,0.49 ± 0.03, 0.30 ± 0.03, respectively. After treated with ropivacaine hydrochloride for 4h, the expression levels of IFN- α ,IFN- β ,IFNAR1 and IFNAR2 were 0.55 ± 0.08,0.72 ± 0.05,0.9 ± 0.01,0.59 ± 0.06, respectively. Compared with the normal group, the expression levels of IFN- α ,IFN- β ,IFNAR1 and IFNAR2 of the cell in ropivacaine group significantly up-regulated, Fig. 4.



Fig. 2A. The represent sample of the cell apoptosis rate. B:The cell apoptosis rate of the cells in each group. (Mean ±SD, n=3). ^aP<0.05 vs the cells in normal group



Fig. 3. The mRNA expression of IFN- α (A), IFN- β (B), IFNAR1(C) and IFNAR2 (D). (Mean ±SD, n=3). ^aP<0.05 vs the cells in normal group

3.5 The Level of IL-6, IL-10 and TNF – α

The level of IL-6, IL-10 and TNF - α of the cell culture medium in Normal group were (42.04 ± 0.31) pg/ml, (87.71 ± 0.64) pg/ml and (28.45 ± 0.18) pg/ml, respectively. After treated with 3mM ropivacaine hydrochloride for 4 h, the level of IL-6, IL-10 and TNF- α of the cell culture medium were significantly increased, which were (155.08 ± 0.53) pg/ml, (29.99 ± 0.23) pg/ml and (109.25 ± 0.46) pg/ml, respectively.

4. DISCUSSION

In this study, SH-SY5Y cells were treated with 3mM ropivacaine hydrochloride for 4h to construct the local anesthetics neurotoxicity cell model in vitro. The concentration and expose time of ropivacaine hydrochloride were referred to previous study [17]. The results showed that

the cell viability decreased and the apoptosis rate increased after treated with 3 mM ropivacaine hydrochloride for 4 h, indicating that the model of cell injury in vitro was successful.

Type I interferon can resist the infection of virus, bacteria and other microorganisms.As well as, the increased expression of type I interferon can aggravate the damage of central nervous system, lead to inflammatory reaction, and is not conducive to the repair of neurons. I - IFN promotes inflammatory response, induces proinflammatory gene transcription, promotes the secretion of inflammatory factors (TNF - α, IL-6, IL-1 β) through a variety of signal cascades, including the classic JAK1-STAT signaling pathway, which aggravates the inflammatory reaction and causes damage to the body[18-22]. The results in this study showed that the expressions of IFN-α, IFN-β, IFNAR1 and

IFNAR2 were up-regulated, and the concentration of inflammatory factors IL-6, IL-10 and TNF - a were increased after 4 h treatment with 3 mM ropivacaine hydrochloride. Those results suggest that the neurotoxic injury of ropivacaine hydrochloride is related to inflammatory reaction, and type I interferon and its receptor may participate in the nerve injury induced by ropivacaine hydrochloride.

The mechanism of I - IFN involved in the neurotoxicity of ropivacaine hydrochloride is still unclear. It has been reported that I - IFN binds to IFNAR receptor and phosphorylates, activates JAK1-STAT signal transduction system, promotes the secretion of inflammatory factors, and leads to cell damage[20]. I - IFN mediated aseptic inflammatory reaction is also one of the mechanisms leading to cell damage. In the nerve injury induced by local anesthetics, we speculate

that I - IFN expression is up-regulated, and its receptor IFNAR is phosphorylated to activate its downstream JAK1 signal pathway, thus mediating JAK1 / STAT (STAT1 and stat2) signal transduction, activating IFN stimulating gene transcription in nucleus, and expressing related proteins, inducing Inflammation occurs, leading to nerve cell damage.

In this study, the correlation between I - IFN and ropivacaine hydrochloride nerve injury was observed. It was confirmed that I - IFN and IFNAR were involved in the neurotoxicity of ropivacaine hydrochloride. It is a limitation of this study that the effects of I – IFN on the toxicity of the ropivacaine hydrochloride in vivo have not been investigated. At the same time, the specific mechanism of I - IFN and IFNAR involved in ropivacaine nerve injury needs further experimental confirmation.



Fig. 4. The protein expression of IFN-α(A), IFN-β(B), IFNAR1(C) and IFNAR2 (D) detected with western blotting. (Mean ±SD, n=3). ^a*P*<0.05 vs the cells in normal group



Fig. 5. The level of IL-6, IL-10 and TNF – α of the cell culture medium detected with ELISA (Mean ±SD, n=3). ^aP<0.05 vs the cells in normal group

5. CONCLUSION

The expression of I - IFN and IFNAR of the SH-SY5Y cells treated with ropivacaine hydrochloride up-regulate and the concentration of IL-6, IL-10 and TNF – α increase. I - IFN and IFNAR are related to the neurotoxicity of ropivacaine hydrochloride.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

ACKNOWLEDGMENTS

Project funded by China Postdoctoral Science Foundation (No.2019M653289) and Foshan medical science and technology project (No.1920001000725)

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

Wen et al.; JPRI, 32(22): 1-10, 2020; Article no.JPRI.61002

REFERENCES

- Gun SY, Claser C, Tan KS, Rénia L. Interferons and interferon regulatory factors in malaria. Mediators Inflamm. 2014;2014:243713. DOI:10.1155/2014/243713
- Capobianchi MR, Uleri E, Caglioti C, Dolei A. Type I IFN family members: similarity, differences and interaction. Cytokine Growth Factor Rev. 2015;26(2):103-111. DOI:10.1016/j.cytogfr.2014.10.011
- Durbin RK, Kotenko SV, Durbin JE. Interferon induction and function at the mucosal surface. Immunol Rev. 2013;255(1):25-39. DOI:10.1111/imr.12101
- De Weerd NA, Nguyen T. The interferons and their receptors--distribution and regulation. Immunol Cell Biol. 2012;90(5):483-491. DOI:10.1038/icb.2012.9
- Nallar SC, Kalvakolanu DV. Interferons, signal transduction pathways, and the central nervous system. J Interferon Cytokine Res. 2014;34(8):559-576. DOI:10.1089/jir.2014.0021
- Choubey D. Type I interferon (IFN)inducible Absent in Melanoma 2 proteins in neuroinflammation: implications for Alzheimer's disease. J Neuroinflammation. 2019;16(1):236. DOI:10.1186/s12974-019-1639-5
- Boyle DL, Soma K, Hodge J, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1311-1316.
- DOI:10.1136/annrheumdis-2014-206028
- Danziger O, Pupko T, Bacharach E, Ehrlich M. Interleukin-6 and Interferon-α Signaling via JAK1-STAT Differentially Regulate Oncolytic versus Cytoprotective Antiviral States. Front Immunol. 2018;9:94. DOI:10.3389/fimmu.2018.00094
- Owen KL, Brockwell NK, Parker BS. JAK-STAT Signaling: A double-edged sword of immune regulation and cancer progression. Cancers (Basel). 2019;11(12):2002. DOI:10.3390/cancers11122002
- Liu Y, Gibson SA, Benveniste EN, Qin H. Opportunities for translation from the bench: therapeutic intervention of the JAK/STAT pathway in neuroinflammatory diseases. Crit Rev Immunol. 2015;35(6):505-527. DOI:10.1615/CritRevImmunol.2016015517

- 11. Zhang K, Yang S, Luo C. TNF-alpha and TNF-R1 regulate bupivacaine-induced apoptosis in spinal cord dorsal root ganglion neuron. Eur J Pharmacol. 2018;833:63-68. DOI:10.1016/j.ejphar.2018.05.034
- Kan H, Wang Y, Wang D, et al. Cordycepin rescues lidocaine-induced neurotoxicity in dorsal root ganglion by interacting with inflammatory signaling pathway MMP3. Eur J Pharmacol. 2018;827:88-93. DOI:10.1016/j.ejphar.2018.01.049
- Piegeler T, Votta-Velis EG, Bakhshi FR, et al. Endothelial barrier protection by local anesthetics: ropivacaine and lidocaine block tumor necrosis factor-αinduced endothelial cell Src activation. Anesthesiology. 2014;120(6):1414-1428. DOI:10.1097/ALN.00000000000174
- Gray A, Marrero-Berrios I, Weinberg J, et al. The effect of local anesthetic on proinflammatory macrophage modulation by mesenchymal stromal cells. Int Immunopharmacol. 2016;33:48-54. DOI:10.1016/j.intimp.2016.01.019
- Wen X, Li Y, Liu X, et al. Roles of CaMKIIβ in the neurotoxicity induced by ropivacaine hydrochloride in dorsal root ganglion. Artif Cells Nanomed Biotechnol. 2019;47(1):2948-2956. DOI:10.1080/21691401.2019.1642208
- Wen X, Liang H, Li H, et al. In vitro neurotoxicity by ropivacaine is reduced by silencing Cav3.3 T-type calcium subunits in neonatal rat sensory neurons. Artif Cells Nanomed Biotechnol. 2018;46(8):1617-1624.

DOI:10.1080/21691401.2017.1384386

- 17. Wen X, Lai X, Li X, Zhang T, Liang H. The effects of ropivacaine hydrochloride on the expression of CaMK II mRNA in the dorsal root ganglion neurons. Biomed Pharmacother. 2016;84:2014-2019. DOI:10.1016/j.biopha.2016.11.018
- Chen K, Liu J, Cao X. Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review. J Autoimmun. 2017;83:1-11. DOI:10.1016/j.jaut.2017.03.008
- Taylor JM, Minter MR, Newman AG, Zhang M, Adlard PA, Crack PJ. Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer's disease. Neurobiol Aging. 2014;35(5):1012-1023. DOI:10.1016/j.neurobiolaging.2013.10.089

Wen et al.; JPRI, 32(22): 1-10, 2020; Article no.JPRI.61002

- 20. Palanivel JA, Macbeth AE, Chetty NC, Levell NJ. An insight into JAK-STAT signalling in dermatology. Clin Exp Dermatol. 2014;39(4):513-518. DOI:10.1111/ced.12273
- 21. Goldmann T, Blank T, Prinz M. Fine-tuning of type I IFN-signaling in microglia-implications for homeostasis, CNS

autoimmunity and interferonopathies. Curr Opin Neurobiol. 2016;36:38-42. DOI:10.1016/j.conb.2015.09.003

22. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5): 375-386. DOI:10.1038/nri1604

© 2020 Wen et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history: The peer review history for this paper can be accessed here: http://www.sdiarticle4.com/review-history/61002